COST-EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN BULGARIA, 2016

被引：0
|
作者：
Djambazov, S. [1 ]
Vekov, T. [1 ]
机构：
[1] Med Univ Pleven, Pleven, Bulgaria
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND31
引用
收藏
页码：A193 / A193
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States
    Chirikov, Viktor
    Ma, Ingrid
    Joshi, Namita
    Patel, Dipen
    Smith, Alden
    Giambrone, Cindy
    Cornelio, Noelle
    Hashemi, Lobat
    VALUE IN HEALTH, 2019, 22 (02) : 168 - 176
  • [2] COST-EFFECTIVENESS OF ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Kohn, Christine G.
    Costales, Victoria
    Coleman, Craig I.
    Young, Dan
    Limone, Brendan L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1413 - 1414
  • [3] Cost-Effectiveness Analysis of Multiple Sclerosis Treatment Approaches
    Hola, Martina
    Gajdos, Ondrej
    Kamensky, Vojtech
    Kubincova, Karolina
    ADVANCES IN DIGITAL HEALTH AND MEDICAL BIOENGINEERING, VOL 2, EHB-2023, 2024, 110 : 69 - 77
  • [4] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [5] COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN GREECE
    Kourkoulas, N.
    Athanasakis, K.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2018, 21 : S339 - S339
  • [6] COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN CYPRUS
    Kourkoulas, N.
    Athanasakis, K.
    Theodorou, M.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2018, 21 : S340 - S340
  • [7] COST-EFFECTIVENESS ANALYSIS OF FAMPRIDINE FOR MULTIPLE SCLEROSIS TREATMENT IN CHINA
    Zhao, X.
    Yang, H.
    Zhao, J.
    Wei, T.
    Liu, J.
    VALUE IN HEALTH, 2022, 25 (07) : S413 - S413
  • [8] THE COST-EFFECTIVENESS OF ALEMTUZUMAB IN THE MANAGEMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Stanisic, S.
    Bertolotto, A.
    Berto, P.
    Di Procolo, P.
    Morawski, J.
    VALUE IN HEALTH, 2018, 21 : S338 - S338
  • [9] The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy
    Stanisic, Sanja
    Bertolotto, Antonio
    Berto, Patrizia
    Di Procolo, Paolo
    Morawski, Julia
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2019,
  • [10] COST-EFFECTIVENESS OF ALEMTUZUMAB IN THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS IN THE UNITED STATES AND SOCIETAL SPILLOVER EFFECTS
    Chirikov, V
    Ma, I
    Joshi, N.
    Patel, D.
    Smith, A.
    Giambrone, C.
    Cornelio, N.
    Hashemi, L.
    VALUE IN HEALTH, 2017, 20 (09) : A722 - A722
12345